PCSA - Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing | Benzinga
Processa Pharmaceuticals Inc (NASDAQ:PCSA) shares are trading higher by 36.9% to $0.28 during Friday’s session after the company announced plans to expand the development of Next Generation Capecitabine (“NGC-Cap”) into the treatment of advanced or metastatic breast cancer.
What Else?
Following discussions with the FDA, the company has decided to conduct a Phase ...
PCSA) Stock Is Skyrocketing>Full story available on Benzinga.com